Related Experiment Video

Updated: Jul 20, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K

TNM-based risk eligibility for adjuvant trials in renal cell carcinoma

Jens Bedke1, Axel Bex2

  • 1Department of Urology and Transplantation Surgery, Klinikum Stuttgart-Katharinenhospital, 70174 Stuttgart, Germany; Stuttgart Cancer Center-Tumorzentrum Eva Mayr-Stihl, Stuttgart, Germany.

Lancet (London, England)
|July 31, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.7K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

25.3K

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
159